Clinical Oncology
Volume 22, Issue 6 , Pages 464-468 , August 2010

Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma

  • S.I. Sherman

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: S.I. Sherman, Department of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, University of Texas M. D. Anderson Cancer Center, PO Box 301402, Houston, TX 77230-1402, USA. Tel: +1-713-792-2841; Fax: +1-713-794-4065. (S.I. Sherman).

Received 25 February 2010 ,Accepted 25 March 2010.

References 

  1. Poster DS, Bruno S, Penta J, Pina K, Catane R. Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin Trials. 1981;4:301–307
  2. Sherman SI. Clinical trials for thyroid carcinoma: past, present, and future. In:  Mazzaferri EL,  Harmer C,  Mallick UK,  Kendall-Taylor P editor. Practical management of thyroid cancer: a multidisciplinary approach. London: Springer; 2006;p. 429–434
  3. Braga-Basaria M, Ringel MD. Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab. 2003;88:1947–1960
  4. Schweppe RE, Klopper JP, Korch C, et al. DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93(11):4331–4341
  5. Tsimberidou AM, Vaklavas C, Wen S, et al. Phase I clinical trials in 56 patients with thyroid cancer: the M.D. Anderson Cancer Center experience. J Clin Endocrinol Metab. 2009;94(11):4423–4432
  6. Harada T, Nishikawa Y, Suzuki T, Ito K, Baba S. Bleomycin treatment for cancer of the thyroid. Am J Surg. 1971;122:53–57
  7. Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res. 1970;30:2572–2582
  8. Gottlieb JA, Hill CS, Ibanez ML, Clark RL. Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. Cancer. 1972;30:848–853
  9. Gottlieb JA, Hill CS. Chemotherapy of thyroid cancer with adriamycin: experience with 30 patients. N Engl J Med. 1974;290:193–197
  10. Burgess MA, Hill CS. Chemotherapy in the management of thyroid cancer. In:  Greenfield LD editors. Thyroid cancer. W. Palm Beach: CRC Press; 1978;p. 233–245
  11. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999;16:34–41
  12. Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2008;40:210–213
  13. Gottlieb JA, Drewinko B. Review of the current clinical status of platinum coordination complexes in cancer chemotherapy. Cancer Chemother Rep. 1975;59:621–628
  14. Rozencweig M, Nicaise C, Beer M, et al. Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol. 1983;1:621–626
  15. Joss RA, Kaplan S, Goldhirsch A, Sessa C, Brunner KW, Cavalli F. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Invest New Drugs. 1984;2:297–304
  16. Hoskin PJ, Harmer C. Chemotherapy for thyroid cancer. Radiother Oncol. 1987;10:187–194
  17. Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 1990;76:480–483
  18. Leaf AN, Wolf BC, Kirkwood JM, Haselow RE. Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group study (E1385). Med Oncol. 2000;17:47–51
  19. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155–2160
  20. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:405–407
  21. Bukowski RM, Brown L, Weick JK, Groppe CW, Purvis J. Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol. 1983;6:579–581
  22. Argiris A, Agarwala SS, Karamouzis MV, Burmeister LA, Carty SE. A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs. 2007;26:183–188
  23. Biganzoli L, Gebbia V, Maiorino L, Caraci P, Iirillo A. Thyroid cancer: different outcomes to chemotherapy according to tumour histology. Eur J Cancer. 1995;31A:2423–2424
  24. Santini F, Bottici V, Elisei R, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;87:4160–4165
  25. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Thyroid. 2000;10:587–594
  26. Ikeda M, Tanaka K, Sonoo H, et al. Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma. Gan To Kagaku Ryoho. 2007;34:933–936
  27. Matuszczyk A, Petersenn S, Voigt W, et al. Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2010;42:61–64
  28. Hanauske AR, Lahn M, Musib LC, et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol. 2009;20:1565–1575
  29. Hanauske A-R, Dumez H, Piccart M, et al. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs. 2009;27:356–365
  30. Saller B. Treatment with cytotoxic drugs. In:  Biersack H,  Grunwald F editor. Thyroid cancer. Springer; 2005;p. 171–186[Chapter 10]
  31. Gilliam LK, Kohn AD, Lalani T, et al. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid. 2006;16(8):801–810
  32. Alexandre J, Kahatt C, Bertheault-Cvitkovic F, et al. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors. Invest New Drugs. 2007;25(5):453–462
  33. Klonisch T, Hoang-Vu C, Hombach-Klonisch S. Thyroid stem cells and cancer. Thyroid. 2009;19(12):1303–1315
  34. Schlumberger M, Sherman SI. Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances. Thyroid. 2009;19:1393–1400

PII: S0936-6555(10)00126-3

doi: 10.1016/j.clon.2010.03.014

Clinical Oncology
Volume 22, Issue 6 , Pages 464-468 , August 2010

Article Tools